CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 832 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
azelastine Hcl 548 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00651118
NCT00651118Phase 3Completed
CompareCT.gov

Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

Meda Pharmaceuticals·interventional·Posted Apr 2, 2008·Updated Sep 26, 2012

In Brief

A Phase 3 clinical trial evaluating Placebo, azelastine Hcl, and 2 other interventions for Seasonal Allergic Rhinitis. Completed, enrolled 832 participants across 43 sites.

Detailed Summary

The purpose of this study is to determine if two allergy medications (azelastine and fluticasone) are more effective than placebo or either medication alone (azelastine or fluticasone)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2, 2008
Enrollment StartMar 1, 2008
Primary CompletionJun 1, 2008
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.3 years ago

Interventions

Placebodrug

placebo

azelastine Hcldrug

azelastine Hcl 548 mcg

azelastineHcl / fluticasone propionatedrug

azelastine Hcl 548 mcg / fluticasone propionate 200 mcg

fluticasone propionatedrug

fluticasone propionate 200 mcg